FULC Financials: Fulcrum Therapeutics Inc AI Analysis

Home

Stock

FULC

Financials

FULC Financial

Fulcrum Therapeutics Inc

$6.58

-2.22%

$-0.15

At close: Mar 30, 16:00:00 GMT-4

$6.58

Post-market: Mar 30, 20:00:00 GMT-4

Overview Forecast Earnings Dividends Financials

Income

Balance sheet

Cash flow

Annual

Quarterly

FULC Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021
Revenue	0	0	80	2	6	19
Revenue Growth (YoY)	-100%	-100%	3,900%	-67%	-68%	138%
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	--	--	--	--
Selling, General & Admin	21	28	36	41	41	30
Research & Development	42	56	63	71	76	69
Operating Expenses	64	84	99	113	118	100
Other Non Operating Income (Expenses)	7	9	12	13	2	0
Pretax Income	-57	-74	-9	-97	-109	-80
Income Tax Expense	0	0	--	--	--	--
Net Income	-57	-74	-9	-97	-109	-80
Net Income Growth	533%	722%	-91%	-11%	36%	14%
Shares Outstanding (Diluted)	65.8	63.35	61.98	61.31	44.99	35.36
Shares Change (YoY)	7%	2%	1%	36%	27%	39%
EPS (Diluted)	-0.86	-1.18	-0.15	-1.58	-2.44	-2.29
EPS Growth	473%	653%	-90%	-35%	7%	-18%
Free Cash Flow	-60	-60	-2	-91	-99	-80
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	--	--	--	--	--	--
Operating Margin	0%	0%	-23.75%	-5,500%	-1,866.66%	-426.31%
Profit Margin	0%	0%	-11.25%	-4,850%	-1,816.66%	-421.05%
Free Cash Flow Margin	0%	0%	-2.5%	-4,550%	-1,650%	-421.05%
EBITDA	-63	-83	-18	-108	-110	-79
EBITDA Margin	0%	0%	-22.5%	-5,400%	-1,833.33%	-415.78%
D&A For EBITDA	1	1	1	2	2	2
EBIT	-64	-84	-19	-110	-112	-81
EBIT Margin	0%	0%	-23.75%	-5,500%	-1,866.66%	-426.31%
Effective Tax Rate	0%	0%	--	--	--	--

Follow-Up Questions

What are Fulcrum Therapeutics Inc's key financial statements?



According to the latest financial statement (Form-10K), Fulcrum Therapeutics Inc has a total asset of $366, Net loss of $-74

What are the key financial ratios for FULC?



Fulcrum Therapeutics Inc's Current ratio is 21.52, has a Net margin is 0, sales per share of $0.

How is Fulcrum Therapeutics Inc's revenue broken down by segment or geography?



Fulcrum Therapeutics Inc largest revenue segment is Biopharmaceutical, at a revenue of 80,000,000 in the most earnings release.For geography, United States is the primary market for Fulcrum Therapeutics Inc, at a revenue of 80,000,000.

Is Fulcrum Therapeutics Inc profitable?



no, according to the latest financial statements, Fulcrum Therapeutics Inc has a net loss of $-74

Does Fulcrum Therapeutics Inc have any liabilities?



yes, Fulcrum Therapeutics Inc has liability of 17

How many outstanding shares for Fulcrum Therapeutics Inc?



Fulcrum Therapeutics Inc has a total outstanding shares of 66.57

Key Stats

Prev.Close

$6.73

Open

$6.89

Day's Range

$6.47 - $6.89

52 week range

$2.31 - $15.74

Volume

528.1K

Avg.Volume

994.9K

Dividend yield

EPS (TTM)

-0.90

Market Cap

$438.2M

What is FULC?

Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 45 full-time employees. The company went IPO on 2019-07-18. The firm's lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease (SCD). The company uses technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. In addition to its product candidates, the Company has developed a discovery approach that it employs to systematically identify and validate cellular drug targets that can potentially modulate gene expression to treat known root causes of genetically defined rare diseases. The firm continues to advance its program for the potential treatment of inherited aplastic anemias, such as Diamond-Blackfan anemia (DBA), Shwachman-Diamond syndrome, and Fanconi anemia.



Features

AI Copilot for Stock & Crypto

Resources